Avalo Therapeutics appoints Keith Maher, MD to Board under Armistice Capital right

Avalo Therapeutics, Inc.

Keith Maher, MD appointed to board effective Oct 15, 2021; term until 2022 annual meeting.
Maher is employed by Armistice Capital Master Fund, a significant stockholder; CIO Steven J. Boyd already on board.
Armistice participated in five offerings since Feb 2020, including 5.45M shares in Sept 2021 offering raising $29.3M net.
Armistice purchased shares in each offering on same terms as other investors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Keith Maher, MD

director

AVTX · Avalo Therapeutics, Inc.

Effective: 2021-10-15
Filed: October 18, 2021, 7:59 PM ET

On October 15, 2021, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Keith Maher, MD, to the Board, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Maher, MD was appointed as director at Avalo Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On October 15, 2021, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Keith Maher, MD, to the Board, effective immediately

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-21-020176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.